Medicine and Dentistry
Paclitaxel
100%
Bevacizumab
63%
Overall Survival
27%
Progression Free Survival
27%
Metastatic Breast Cancer
27%
Hazard Ratio
18%
Patient
18%
Inpatient
18%
Hypertension
9%
Survival Rate
9%
Brain Ischemia
9%
Combination Therapy
9%
Febrile Neutropenia
9%
Headache
9%
Infection
9%
Vasculotropin
9%
Proteinuria
9%
Body Weight
9%
Monoclonal Antibody
9%
Body Surface
9%
Therapeutic Procedure
9%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Bevacizumab
63%
Overall Survival
27%
Progression Free Survival
27%
Metastatic Breast Cancer
27%
Survival Rate
9%
Brain Ischemia
9%
Febrile Neutropenia
9%
Hypertension
9%
Monoclonal Antibody
9%
Infection
9%
Headache
9%
Vasculotropin
9%
Proteinuria
9%
INIS
patients
36%
cancer
27%
comparative evaluations
27%
metastases
27%
breasts
27%
hazards
18%
therapy
9%
growth factors
9%
safety
9%
hypertension
9%
ischemia
9%
weight
9%
monoclonal antibodies
9%
surface area
9%
meters
9%